본 보고서는 5개 이상의 회사, 5개 이상의 HSV-1 각막염 치료제에 대한 종합적인 인사이트를 제공합니다. 이 보고서는 제품 유형, 개발 단계, 투여 경로, 분자 유형별로 치료제를 평가합니다. 또한, 이 분야에서 개발이 중단되거나 비활성화된 파이프라인 제품도 다루고 있습니다.
본 보고서는 등재된 의약품에 대한 상업적 평가, 협업, 계약, 라이선싱, 인수 관련 거래 금액의 추이도 다루고 있습니다.
기업 및 제품 프로필 : 시판 중인 의약품
기업 및 제품 프로필 : 파이프라인 치료제
DelveInsight's, " HSV-1 Keratitis- Competitive landscape, 2025," report provides comprehensive insights about 5+ companies and 5+ drugs in HSV-1 Keratitis Competitive landscape. It covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
HSV-1 Keratitis: Understanding
HSV-1 Keratitis: Overview
HSV-1 keratitis is a viral infection of the cornea caused by the herpes simplex virus type 1 (HSV-1). It is the most common cause of corneal blindness in developed countries. HSV-1 is typically associated with oral infections like cold sores, but it can also infect the eye, leading to keratitis. The virus can be transmitted through direct contact with infected secretions, often spreading to the eye via contaminated fingers or through the bloodstream from a primary infection elsewhere. Herpes simplex keratitis is primarily diagnosed by conducting a thorough clinical evaluation of patients suspected of having the condition, including history-taking and slit-lamp examination. HSV-1 keratitis typically presents with symptoms such as eye pain, redness, blurred vision, and sensitivity to light (photophobia), and tearing.
Patients may also experience a foreign body sensation in the eye. In recurrent cases, the symptoms can vary and may include decreased vision or visual disturbances due to corneal scarring. The infection often recurs, with the virus remaining latent in the trigeminal ganglion and reactivating during periods of stress, illness, or immunosuppression.
HSV-1 Keratitis potential complications include; Corneal ulcers or dendritic ulcers, Corneal scarring, which can lead to vision impairment and Recurrence of infection, which can cause repeated episodes of symptoms. The pathophysiology of HSV-1 keratitis involves the reactivation of the latent virus, which travels down the sensory nerves to the cornea. The infection initially affects the superficial layers of the cornea, leading to epithelial keratitis, characterized by the presence of dendritic ulcers branching lesions on the cornea. If the infection progresses, it can involve deeper layers, causing stromal keratitis, which can lead to scarring, thinning of the cornea, and, ultimately, vision loss. The immune response to the virus also contributes to corneal damage, as the body's attempt to eliminate the virus can result in inflammation and tissue destruction.
The diagnosis of HSV-1 keratitis is primarily clinical, based on the characteristic appearance of dendritic ulcers on slit-lamp examination. Fluorescein staining of the cornea can enhance the visibility of these ulcers, which appear as bright, branching patterns. In uncertain cases, laboratory tests such as polymerase chain reaction (PCR) or viral culture from corneal scrapings can confirm the presence of HSV-1. Serological tests are generally not useful in acute cases but may help in distinguishing between primary and recurrent infections.
The treatment of HSV-1 keratitis typically involves antiviral medications, either topical or oral. Topical antiviral eye drops, such as trifluridine or ganciclovir, are commonly used to treat epithelial keratitis. Oral antivirals like acyclovir or valacyclovir may be prescribed, especially in cases of recurrent infections or to reduce the risk of recurrence. In cases of stromal keratitis, corticosteroids may be added to the treatment regimen to reduce inflammation, but these must be used cautiously to avoid exacerbating the viral infection. Long-term prophylactic antiviral therapy may be considered for patients with frequent recurrences to prevent further episodes and reduce the risk of corneal scarring.
HSV-1 Keratitis: Company and Product Profiles (Marketed Therapies)
Novartis International AG is a global healthcare company based in Switzerland, and one of the largest pharmaceutical companies in the world. Founded in 1996 through the merger of Ciba-Geigy and Sandoz, Novartis is involved in the research, development, manufacturing, and marketing of a broad range of healthcare products, with a focus on pharmaceuticals, generics, and biosimilar. Novartis has committed to sustainable healthcare solutions, including efforts to reduce environmental impact and improve global access to medicines. It also works on initiatives to provide affordable drugs in low- and middle-income countries.
Product Description: Famciclovir
Famciclovir is an antiviral medication used to treat infections caused by herpes viruses, including herpes simplex (HSV-1 and HSV-2). Famciclovir is a prodrug that is converted into penciclovir in the body, which works by inhibiting viral DNA replication, effectively controlling viral infections. Famciclovir (Famvir) is an oral antiviral medication that is being studied for its efficacy in treating herpes simplex virus (HSV) keratitis. Famvir has a long intracellular half-life, which may allow for persistent antiviral activity. It was originally developed and marketed by Novartis. Famvir(R) is a registered trademark of Novartis International Pharmaceutical Ltd.
HSV-1 Keratitis: Company and Product Profiles (Pipeline Therapies)
Shanghai BD gene Co., Ltd. is a biotechnology company based in Shanghai, China. The company is involved in the development and commercialization of genetic and genomic technologies. BD gene specializes in providing genetic testing services, including genetic disease screening, drug metabolism testing, and personalized medicine. The company offers a range of products and services related to genomics, including high-throughput sequencing technologies and bioinformatics solutions. The company is involved in developing personalized medicine solutions, which involve tailoring medical treatment to the individual characteristics of each patient based on their genetic profile.
Product Description: Difelikefalin BD-111
BD111 is a gene editing treatment for viral keratitis developed based on BD mRNA delivery patent technology, and has completed 3 human clinical trials of IIT. It is the only technology of Cas9 mRNA delivery by lentivirus in the world, and also the second human clinical research project of CRISPR-Cas9 gene editing treatment in human body in the world. The drug uses bdgene's original delivery technology VLP to transduce CRISPR, directly target and cut the genome of HSV-1, so as to eliminate the genome of HSV-1 virus and achieve the treatment of herpesvirus keratitis. BD111 is characterized by delivering cas9 mRNA, the gene enzyme stays in the body for a short time, which can reduce the immune response and reduce the risk of gene editing miss; it edits the viral genome, does not need to change any human genes, and has not detected the off target effect on the human genome. The drug is in Phase II stage of the development for HSV-1 Keratitis.
HSV-1 Keratitis Analytical Perspective by DelveInsight
The Report provides in-depth commercial assessment of drugs that have been included, which comprises collaboration, agreement, licensing and acquisition - deals values trends. The sub-segmentation is described in the report which provide company-company collaboration (licensing/partnering), company academic collaboration and acquisition analysis in tabulated form.
The report comprises of comparative assessment of Companies (by therapy, development stage, and technology).
Current Treatment Scenario and Emerging Therapies:
Key Players
Key Products
Introduction
Executive Summary
HSV-1 Keratitis: Overview
HSV-1 Keratitis-Analytical Perspective: In-depth Commercial Assessment
Competitive Landscape
Therapeutic Assessment
HSV-1 Keratitis: Company and Product Profiles (Marketed Therapies)
Novartis
Famciclovir
HSV-1 Keratitis: Company and Product Profiles (Pipeline Therapies)
Late Stage Products (Phase III)
Company Name
Product Name
Mid Stage Products (Phase II)
Shanghai BDgene Co., Ltd
BD-111
Early Stage Products (Phase I)
Company Name
Product Name
Preclinical and Discovery Stage Products
Company Name
Product Name
Inactive Products
HSV-1 Keratitis- Unmet needs
HSV-1 Keratitis- Market drivers and barriers